IMNN · Imunon, Inc.

Imunon continued to incur significant operating losses in Q1 FY2026, with operating income at -$4.3 million, a 3.9% widening from -$4.1 million in the prior year quarter. This reflects the Company's ongoing investment in research and development activities, particularly the ramp-up of Phase 3 OVATION 3 trial enrollment for IMNN-001 and related preclinical studies. Net income followed suit at -$4.2 million, up 3.6% from -$4.1 million YoY, resulting in diluted EPS of -$0.84 versus -$0.28 last year—a 200% deterioration attributable to share count expansion funding these clinical efforts. Management notes that since inception, the Company has experienced negative cash flows from operations, expecting significant operating losses ahead due to R&D and general administrative expenses.

Cash flow dynamics underscore the liquidity pressures of a clinical-stage biotech. Net cash used in operating activities reached -$4.0 million, up from -$2.8 million YoY, as trial-related costs and program development accelerated. Capital expenditures remained stable at $260K, producing free cash flow of -$4.2 million. This flexible vaccine platform benefits from an established supply chain for plasmid vectors and formulations, enabling efficient advancement. However, the inability to complete trials timely or secure collaborations could elevate capital needs and strain liquidity, as highlighted in management commentary.